Skip to main content
. Author manuscript; available in PMC: 2022 Sep 8.
Published in final edited form as: Lancet Oncol. 2021 Dec 11;23(1):149–160. doi: 10.1016/S1470-2045(21)00589-1

Figure 4: Prognostic value of RCB class for hormone receptor and HER2 subtypes.

Figure 4:

Kaplan-Meier plots of event-free survival by RCB classes among breast cancer subtypes. For the two HER2-positive subtypes, plots of the subset of patients who received neoadjuvant HER2-targeted therapy are shown (plots for all HER2-positive patients, with or without HER2-targeted therapy, are presented in the appendix p 13). Crosses denote patients censored. RCB=residual cancer burden.